International Society of Oncology Pharmacy Practitioners
Vol 19, No. 1 March 2017
Message from the President 


Since ISOPP's 2016 Annual General Meeting (AGM) in Santiago, Chile, ISOPP members have engaged in leadership roles like never before. There are 13 committees, task forces and work groups consisting of over 60 members volunteering their time and all working to move the strategic plan's missions and goals forward. To them I say a big Thank You!! These are exciting times with member engagement at an all-time high. Ten candidates from ten countries on the 2017 election slate ( be sure to vote) is testament to this.

Another important milestone since the 2016 AGM, is that ISOPP continues to make progress with the process of incorporation in Canada. Following the membership approval of moving forward with incorporation in Canada, the ISOPP Secretariat and Governance Committee have worked closely with legal representation from Canada to facilitate a smooth transition. The goal of this work is to assure our bylaws continue to accurately represent our organization's mission and values and were adapted to maintain alignment with our historic bylaws and meet all legal requirements.

ISOPP's Bylaws are currently under review by the members. The review period will end on Friday, March 31, 2017, after which, the membership will be asked to vote electronically on the acceptance of the bylaws. We invite questions and feedback. Visit the bylaw review page on the ISOPP website  for more information and frequently asked questions (log in as a member to view). 

Also, in response to priority three of the strategic plan: "Mobilize oncology pharmacy community around collaborative advocacy initiatives", ISOPP is organizing a Global Oncology Pharmacy Summit taking place immediately prior to the 2017 Symposium in Budapest at the Budapest Marriott Hotel on April 24 and 25, 2017.

The purpose of the Summit is to start the conversation on how to advance global cancer care though collaborative action. The desired outcome is to support advancements in global cancer care through collaborative action. You can learn more at the 2017 Symposium, through our member communications, postings to the website and through social media. In the meantime, please assist us to gather some baseline information with respect to advocacy activities related to drug access that Oncology Pharmacists engage in at the institutional/regional/national and international level(s) by completing a 5 minute survey ahead of the Summit and by March 31, 2017.

Click here to complete the survey:

We also ask you to share the survey link with any and all colleagues you know that engage in any of these activities. Participation is voluntary and can be done anonymously. We request contact information for the sole purpose of clarifying any responses.

With the 2017 elections (log in as a member to view) underway, I am looking forward to our Annual General Meeting (AGM) taking place on Thursday, April 27, 2017 from 11:30 to 12:30 (CEST) at the Budapest Marriott Hotel and the opportunity to see you and talk with you. Hope to see you there!!

Enjoy this edition of the Newsletter and all the news about oncology pharmacy around the world including my recent trip to Turkey where I had the honour of presenting ISOPP to our colleagues from the Turkish Society of All Public Pharmacists (TUKED).


Harbans Dhillon
ISOPP President

PS If you missed reading February's Staying in Touch Enews or any other issue this year, visit the  Staying in Touch archive page  on ISOPP's website to catch up. A reminder too, that past editions of the Newsletter are also available on ISOPP's website on the  Newsletter page .
Please check that you received ISOPP's February edition of the Staying in Touch Enews in your inbox and that it did not go into a spam filter or junk folder. 

It contains information on how to vote in the 2017 elections and information on the Bylaw review

Also, please assist ISOPP gather some baseline information with respect to advocacy activities related to drug access that Oncology Pharmacists engage in at the institutional/regional//national and international level(s) by completing a 5 minute survey by March 31, 2017. 

Click here to complete the survey:

The survey results will inform participants at ISOPP's Global Oncology Pharmacy Summit taking place immediately prior to the 2017 Symposium in Budapest at the Marriott Budapest Hotel in April 2017.
OncologyOncology Around the World

Oncology Pharmacy in Hungary OncologyHungary
By  Attila Sz u cs, National Institute of Oncology, Budapest, Hungary

Sadly, Hungary has the highest rate of mortality due to cancer in Europe. Cancer is the second most frequent cause of death following cardiovascular diseases.

In 2000-2003, the number of cancer among the male population increased from 34,359 to 40,366. A breakdown of types of tumour showed that in 2000, lung cancer led the list at 20.5%. Colorectal cancer accounted for 13% of overall tumour morbidity, while oral cavity cancer was third in incidence at 8.1%. In 2000-2003, the rate of morbidity due to lung cancer rose from 145.1 to 155.9 per 100,000 population, while colorectal cancer increased from 92.1 per 100,000 population to 100.2. (Increases in the number of reported cases of prostate and skin cancer also contributed to the rise in incidence, and this reflects an improvement in data reporting.) Malignant tumours are reported to the National Cancer Register by the healthcare institutions. 

Are you attending ISOPP 2017 in Budapest, Hungary? Register to visit the National Institute of Oncology, the only comprehensive cancer centre in Hungary and neighbouring countries. The visit will be guided by Attila Szucs and will take place on Wednesday, April 26th from 13:00 until 14:30. 
At work at the National Institute of Oncology in Budapest
Report of the ASBMT 2017 Meeting ASBMT
By Tiene Bauters, Ghent University Hospital, Ghent, Belgium

I had the pleasure of attending the ASBMT Tandem meetings, that were held in the Gaylord Convention Center, Orlando, USA. The BMT Tandem Meetings are the combined annual meetings of the Center for International Blood and Marrow Transplant Research (CIBMTR) and the American Society of Blood and Marrow Transplantation (ASBMT). Investigators, clinicians, laboratory technicians, clinical research professionals, nurses, pharmacists, administrators and allied health professional attendees can benefit from the full scientific program that addresses the timeliest issues in hematopoietic cell transplantation.  

During the two-day conference, multiple pharmacy leaders within the HCT field and experts from other disciplines provided perspectives in the clinical management of this complex patient population. This year, a record number of pharmacists (over 300) were registered. 

Read more ... 
Tiene Bauters Networking at ASBMT 2017
European Society of Oncology Pharmacy (ESOP) Society Day at European Cancer Congress (ECCO 2017)ECCO
By Q.F. Gustavo Espinoza, REDSANA, Santiago, Chile

Between 27th and 30th of January, the European Cancer Congress 2017 was held. This reunion was carried out in the beautiful city of Amsterdam. Every year, this congress covers the most current scientific developments of every discipline from a multidisciplinary perspective, and how they affect our practice and interdisciplinary knowledge with the purpose of keeping it updated.

On January 27th, the different societies that compose ECCO conducted their "SOCIETY DAY" in which people presented for their members and colleagues. This year, The ESOP program made for "SOCIETY DAY", was focused on 4 topics: Oral chemotherapy, new drugs, Role of the Oncology Pharmacist in the wards and Biosimilars in Oncology.

Read more  ... 
Society Day at ECCO 2017

HOPA, ASBMT, NMDP, ACCP, and ASHP Endorse HCT Pharmacist Role Description Developed by ASBMT Pharmacy SIG
By Steve Stricker, BCOP, Takeda Oncology, Florence, United States
On behalf of the ASBMT Pharmacy SIG

The Advocacy & Policy and Education Working Committees of the ASBMT Pharmacy SIG collaborated to develop an HCT (hematopoietic cell transplant) Pharmacist Role description delineating the role of the pharmacist in HCT practice. The HCT pharmacist is an integral member of the multidisciplinary HCT team who provides a variety of pharmacy and educational services to the healthcare team, the patient, and caregivers in an effort to optimize collaborative, patient-centered care focused on patient safety. The purpose of HCT Role Description document is to educate healthcare professionals, HCT program staff, and pharmacy leadership about the specialty role of the HCT clinical pharmacist. The document addresses the educational background, core competencies, HCT pharmacist interventions as well as the HCT pharmacist's clinical activities.

Read More ... 

Accessed February 15, 2017.

ISOPP President at TUKED's 4th National Congress, March 8-12, 2017Tuked
By Harbans Dhillon, ISOPP President, Kuala Lumpur, Malaysia

I was invited by the President of the Turkish Society of All Public Pharmacists (TÜKED), Mustafa Gönen, to be a keynote speaker at TÜKED's 4th National Congress which took place March 8-12, 2017 at the Hilton Hotel Dalaman on the southwestern coast of Turkey. The weather was cold and raining most of the days which made it excellent for attending the congress. 

The congress was attended by about 700 Turkish pharmacists, and I was made to feel very welcome by Mustafa and his wonderful team. I delivered two talks, one right after the congress opening speeches by Mustafa and Erdoğan Çolak (The President of the Turkish Pharmacists Association-TEB). It was titled "Activities of the International Society of Oncology Pharmacy Practitioners (ISOPP)". I presented the other the next day on "Oncology Pharmacy Practices in the World and USP800" during the oncology session. This talk covered practices from Belgium (contributed by Johan Vandenbroucke and Tiene Bauters), Canada (contributed by John Wiernikowski) and Malaysia. It also included USP800 as well as the ISOPP standards. Both talks were well received and I had a lot questions on the topics. Another talk during the oncology session was presented by Yücelen Gönen from the Acıbadem Altunizade Hospital titled "Concurrent Drug Usage in Chemotherapy".

Read more  ... 
Harban Dhillon Presenting at TUKED

BOPA 2016 Annual Symposium Reports BOPA
By Bruce Burnett, University of Wolverhampton, Wolverhampton, United Kingdom

The 2016 BOPA annual symposium took place in Manchester and was attended by upwards of 500 delegates. The programme provided a mix of clinical, policy, research and "hot topics", interspersed with some keynote and sponsored sessions.

The topics I have chosen were simply those I attended and found most interesting and which I felt would be more interesting to the wider audience, and are not a reflection on the other content. 

The first session was, for me at least, the best of the symposium. Having an interest in adverse drug reaction identification and reporting meant the session presented by Professor Sir Munir Pirmohamed, David Weatherall Chair in Medicine at the University of Liverpool. He also has a role within the MHRA and he encouraged the audience to complete "yellow-card" reports on adverse reactions to cancer medicines. They do not receive many reports and that reduces their ability to assess their impact and provide advice on avoiding these as well as improving understanding of these events. He started by setting the scene; at Clatterbridge Centre for Oncology in Liverpool an acute of the acute oncology service showed that 41% of admissions, 20% of deaths and 18% of patients with an increased length of stay were a direct result of cancer medicine adverse drug reactions (ADR). The need to consider long term effects due to the improved survival were important and the need to have a composite outcome; event free survival and quality of life for lifespan.

Read more  ... 
Eur. J Cancer 2016; 54: 139 - 148

newsISOPP Business and News

ISOPP's 2017 Annual General Meeting will take place on Thursday, April 27 from 11:30 to 12:30 (CEST) at the Budapest Marriott Hotel in Budapest, Hungary.
Please visit the member section of the website to review the minutes from the 2016 AGM and the 2017 AGM agenda.
Rowena (Moe) Schwartz presenting at the ISOPP Annual General Meeting in Santiago, Chile in 2016

Participants engaging in the ISOPP's 2016 AGM

ISOPP17ISOPP 2017 Symposium
The  XVI International Symposium  will take place April 26-29, 2017 in Budapest, Hungary.
ISOPP is offering rates, which not only include three days of informative, engaging and leading edge program at the Symposium, but also ISOPP membership for 2017.  There are reduced rates for current members, Residents, Students and Allied Health Professionals.

The confirmed plenary speakers are:

World Health Organization Geneva, Switzerland

Clinical Outcomes Group
Bristol, United Kingdom

Mellrákinfó Egyesület (Breast Cancer Information Society) Budapest, Hungary

Universitätsklinikum Carl Gustav Carus
Dresden, Germany

In case you missed the email, read the latest edition of the Staying in Touch Enews on the ISOPP website.  

"Staying in Touch" is a communication from the ISOPP Secretariat to you, the member, who we serve.  The purpose of the communication is to keep you informed of the work the ISOPP leadership is doing on your behalf, and complements the quarterly newsletter that you receive in March, June, September and December.
VJCVirtual Journal Club    
Accessing JOPP is easy! Log in as a member, go to the  JOPP Access page and click the Access JOPP button. You have instant access.

The thirty-sixth issue of the  Virtual Journal Club (VJC)  is available on the International Society of Oncology Pharmacy Practitioners (ISOPP) website. To access it, visit the Virtual Journal Club Surveys page  or follow the  direct link  to the survey. 

"Necitumumab for the treatment of squamous cell non-small cell lung cancer."
Jessica K Brinkmeyer, Donald C Moore. J Oncol Pharm Pract published December 2, 2016.
Learning Objectives:
  1. Describe the mechanism of action of necitumumab(CLL); 
  2. Select appropriate dosing, administration, and pre-medications for necitumumab in combination with cytotoxic chemotherapy; 
  3. Summarize the evidence supporting the efficacy of necitumumab in patients with non-small cell lung cancer ; and 
  4. Identify the most common adverse events and recommend monitoring parameters for necitumumab.
Previous issue:   Thirty-fifth

"Adherence with capecitabine: A population-based analysis based on prescription refill data." 
Kovacic L, de Haan N, de Lemos ML. J Oncol Pharm Pract published October 31, 2016.
Learning Objectives:
  1. To describe the challenges in identifying predictive factors for patient adherence to oral chemotherapy; 
  2. To understand the limitations of commonly used adherence metric in measuring medication adherence for cyclical chemotherapy treatments; and 
  3. Discuss the potential role of using pharmacy refill data in measuring patient adherence to medications.
As a reminder, ISOPP's Virtual Journal Club features online articles from the Journal of Oncology Pharmacy Practice ( JOPP ). Members are encouraged to read articles and then answer a series of multiple choice questions through the  Virtual Journal Club Surveys

After completing the questionnaire, a certificate will be emailed to you. Although not formally accredited for continuing medical education (CME) points, participation is equal to one hour of CME activity.  

Members are also encouraged to use the Member Discussion Forum to stimulate discussion about articles they have read. Your  ISOPP membership  provides many great benefits and we are hopeful you will find the Virtual Journal Club another asset to your oncology pharmacy practice.


Felice Musicco
Website Work Group Key Lead
ISOPP's Society &
Symposium Management Office


Sea to Sky Meeting Management is ISOPP's Society and 2016 & 2017 Symposium Management Office. If you have any questions about membership, services, ISOPP 2016, ISOPP 2017 or the Society, please contact the ISOPP Office directly as follows:
Direct: +1-778-338-4142
Fax: +1-604-984-6434
Suite 206, 201 Bewicke Avenue

North Vancouver, BC Canada V7M 3M7 

In This Issue
Newsletter Summary
This  Newsletter Summary  provides a brief introduction/summary to each article. In order to access the full article, login to the website then click on the 'read more' button at the end of each article's introduction. In addition, at the end of each full article there is the opportunity for you to write comments about the article and start up a discussion forum.

JOPP Access
Accessing JOPP is easy. Log in as a member, go to the   JOPP Access page and click the Access JOPP button. You have instant access.  
E-learning tool Hematopoietic Stem Cell Transplantation
The purpose of Hematopoietic Stem Cell Transplantation (HSCT) E-learning Tool  is to provide basic knowledge to hospital and community pharmacists involved in the pharmaceutical care for HSCT patients. Different topics will be discussed including: hematopoiesis, different types and sources of HSCT, process of HSCT, early and late complications, drugs used during conditioning regimens, drugs used in prevention and treatment of complications. The tool takes approximately 30 minutes to 1 hour to complete, depending on the knowledge and experience of the user.
ISOPP Policy on Endorsement of Guidelines
Do you have a guideline that you would like to submit for ISOPP's endorsement? As per the National Guideline Clearinghouse, guidelines are statements that include recommendations intended to optimize patient care that are informed by a systematic review of evidence and an assessment of the benefits and harms of alternative care options. For further details on eligibility and the evaluation process, review the  ISOPP Policy on Endorsement of Guidelines .
Host a Future 
ISOPP Symposium
Would you like to see one of ISOPP's Symposium held in your city or country?  Review the Destination RFP .

Meet n' Greet
Did you know that you can gather colleagues for an ISOPP "meet n' greet" at a conference you attend to say hello and share the benefits of ISOPP membership?.  

Contact   to find out more.
ISOPP Sponsored Membership Program
The  Sponsored Membership Program  exists  to support 
members who, given their 
personal or regional financial situations, may not be able to become an ISOPP member or continue their ISOPP 

Thanks to the generosity of members who have made 
additional payments, there is 
a pool of money to help support others in the field of oncology pharmacy pay membership fees. Do you know someone who would like to join ISOPP? 


Read more on the program.
Calendar of Events

Upcoming Events around the World
Submit an Article

Contact Evelyn Handel, Newsletter Editor at
to submit an article.
Quick Links